On May 2, 2011, Tradjenta (linagliptin) was approved to be used along with diet and exercise for the treatment of type 2 diabetes. Tradjenta belongs to the class of drugs called DPP-4 inhibitors. DPP-4 inhibitors work by blocking the enzyme DPP-4, which increases the availability of gut hormones called incretins. Incretins help increase insulin production, decrease release of glucose from the liver and delay gastric emptying (helping you to feel full faster). Overall, this action leads to better glucose control—using Tradjenta may help lower A1c up to 0.6%. This medication is given in a 5mg tablet once a day. Tradjenta increases the risk of hypoglycemia (low blood sugar) if you are also taking sulfonylureas or insulin. Tradjenta is similar to other drugs in the DPP-4 class, Januvia and Onglyza. For more information, visit www.tradjenta.com. Talk with your doctor if you think Tradjenta might be right for you.
New med approved for type 2